The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy

[1]  M. Suarez‐Almazor,et al.  Treatment Sequences After Discontinuing a Tumor Necrosis Factor Inhibitor in Patients With Rheumatoid Arthritis: A Comparison of Cycling Versus Swapping Strategies , 2020, Arthritis care & research.

[2]  J. Smolen.  Greetings from the editor , 2020, Annals of the Rheumatic Diseases.

[3]  Tsutomu Takeuchi,et al.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update , 2020, Annals of the Rheumatic Diseases.

[4]  Jennifer M. Cooper,et al.  Development and Validation of the Real-World Progression in Diabetes (RAPIDS) Model , 2019, Medical decision making : an international journal of the Society for Medical Decision Making.

[5]  Y. Okada,et al.  Genetics of rheumatoid arthritis: 2018 status , 2018, Annals of the rheumatic diseases.

[6]  Aldo A. Faisal,et al.  The Artificial Intelligence Clinician learns optimal treatment strategies for sepsis in intensive care , 2018, Nature Medicine.

[7]  J. Smolen,et al.  Diagnosis and Management of Rheumatoid Arthritis: A Review , 2018, JAMA.

[8]  N. Ieronimakis,et al.  A SMART design to determine the optimal treatment of chronic pain among military personnel. , 2018, Contemporary clinical trials.

[9]  R. Caporali,et al.  The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives. , 2017, Autoimmunity reviews.

[10]  M. Dougados,et al.  Efficacy of glucocorticoids, conventional and targeted synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis , 2017, Annals of the rheumatic diseases.

[11]  Charles King,et al.  2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2016, Arthritis & rheumatology.

[12]  G. Burmester,et al.  Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial , 2015, Annals of the rheumatic diseases.

[13]  Bibhas Chakraborty,et al.  Sequential multiple assignment randomized trial (SMART) with adaptive randomization for quality improvement in depression treatment program , 2015, Biometrics.

[14]  P. Emery,et al.  Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study , 2014, Annals of the rheumatic diseases.

[15]  Raveendhara R. Bannuru,et al.  American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis , 2015 .

[16]  M. Dougados,et al.  Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study , 2014, Annals of the rheumatic diseases.

[17]  S. Murphy,et al.  Dynamic Treatment Regimes. , 2014, Annual review of statistics and its application.

[18]  P. Emery,et al.  Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial , 2013, The Lancet.

[19]  J. Kremer,et al.  A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry , 2012, Annals of the rheumatic diseases.

[20]  Vijay S. Pande,et al.  Everything you wanted to know about Markov State Models but were afraid to ask. , 2010, Methods.

[21]  M. Genovese,et al.  Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study , 2009, Annals of the rheumatic diseases.

[22]  Blackford Middleton,et al.  Research Paper: Crossing the Evidence Chasm: Building Evidence Bridges from Process Changes to Clinical Outcomes , 2007, J. Am. Medical Informatics Assoc..

[23]  J. Smolen,et al.  The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. , 2005, Clinical and experimental rheumatology.

[24]  J. Kremer,et al.  The CORRONA database. , 2006, Autoimmunity reviews.

[25]  Erica Moodie,et al.  Dynamic treatment regimes. , 2004, Clinical trials.

[26]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[27]  J J Gómez-Reino Carnota,et al.  [Genetics of rheumatoid arthritis]. , 2000, Medicina clinica.

[28]  S. Soraci,et al.  Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. , 1983, Arthritis and rheumatism.